Jim Cramer's 'Mad Money' CEO Chats: Regeneron and Alkermes
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener .
NEW YORK ( TheStreet) --Every night, Jim Cramer sits down with CEOs and executives on his "Mad Money" show to discuss their business, the economy, politics and more. Today we look back at his recent interviews with Leonard Schleifer, president and CEO of Regeneron
These are excerpts from Cramer's 'Mad Money' Recap, originally published on Jan. 14, 2014.
Executive Decision: Leonard Schleifer
For his "Executive Decision" segment, Cramer spoke with Leonard Schleifer, president and CEO of Regeneron
Schleifer has a lot of positive things to say about Regeneron, noting that despite analysts' calls to the contrary, Eyelea has lots of room to grow thanks to favorable demographics, new geographies and hopefully new indications for the drug later in 2014. Regeneron is also making progress on its anti-cholesterol drug, which the company hopes to file for approval early next year.
Regeneron is also developing promising treatments for the epidemic of allergic diseases that are developing, as well as treatments for genetic ailments.
When asked about the possibility of re-incorporating in Ireland, where the company already has offices, Schleifer said that Regeneron loves New York, where it's headquartered, and has no plans to leave.
Cramer said that Schleifer has made a lot of money for shareholders and he's sticking with the stock.
Executive Decision: Richard Pops
For his "Executive Decision" segment, Cramer spoke with Richard Pops, chairman and CEO of drug maker Alkermes
Pops commented on Alkermes' recent partnership with, of all things, a mutual fund, by saying that drug companies need a strong source of capital and a strong shareholder base, and now Alkermes has a long-term strategy for both. He said his company has five or six blockbuster drugs in development and is now funded to bring them all to market.
Pops explained how its drug, ALKS 5461, is aiming to treat the five million patients a year that are not responding to traditional anti-depressant drugs. Meanwhile, ALKS 3831 hopes to offer those suffering from schizophrenia a drug that requires just six injections a year.
Alkermes is also changing the game when it comes to treating drug addiction with its drug Vivitrol. Pops said that Vivitrol has patent protection for many years to come, giving his company enough time to chip away at the conventional thinking towards drug addiction treatments and to prove the effectiveness to Vivitrol.
Cramer said he remains a believer in both Pops and Alkermes.